OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.…
OraSure Technologies (OSUR) Sees Activist Pressure Ease After Reaching Agreement with Altai Capital
OraSure Technologies (NASDAQ: OSUR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 500 employees.
The shares were at 3.460 USD on 20 November 2026, up 44.2% over 52 weeks. Its 52-week range is 2.080 USD to 4.580 USD: the price is 24.5% below the high and 66.3% above the low.
Its market capitalisation is 238.90M USD.
OraSure Technologies reports return on equity of -20.2%, an operating margin of -58.2% and revenue up 14.1% year over year.
It holds more cash than debt, a net cash position of 136.59M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 5.500 USD is 59.0% above the current price. The next earnings report is expected on 24 February 2027.